• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Brian Buntz

About Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

ProMed Pharma begins preclinical testing of resorbable contraceptive implant

April 20, 2022 By Brian Buntz

ProMed

After receiving funding from the Bill & Melinda Gates Foundation, ProMed Pharma has begun preclinical evaluation of a novel fully resorbable contraceptive implant. The Plymouth, Minnesota–based company imagines that the contraceptive implants could ultimately find use in low- and middle-income (LMIC) settings. The novel implant potentially could offer women 18 months of contraception through the […]

Filed Under: Drug-Device Combinations, Implants, Women's Health Tagged With: Bill & Melinda Gates Foundation, contraceptive implants, levonorgestrel, ProMed Pharma

California aims to produce inexpensive insulin

January 11, 2022 By Brian Buntz

Diabetes

California Governor Gavin Newsom has signaled that the state would pursue manufacturing insulin to offer the hormone at a reduced cost to people with diabetes. “Insulin should not drain your bank account,” Newsom shared over Twitter. Newsom has also made contract manufactured insulin part of the proposed budget planning for the fiscal year 2022. Get […]

Filed Under: Diabetes Tagged With: California, insulin

Lilly pays $50 million upfront to use Entos Pharmaceuticals’ Fusogenix nucleic acid delivery technology

January 6, 2022 By Brian Buntz

Entos/Lilly

Eli Lilly (NYSE:LLY) has acquired exclusive rights to Entos Pharmaceuticals’ Fusogenix proteolipid vehicle (PLV) drug-delivery technology. Indianapolis-based Lilly plans on using the platform to discover and develop nucleic acid products intended for the nervous system. Lilly is optimistic that Fusogenix could help it address hurdles tied to nucleic acid therapeutic modalities. Get the full story […]

Filed Under: Pharmaceuticals, Research & Development Tagged With: Eli Lilly, Entos Pharmaceuticals, Fusogenix, nucleic acid therapeutic modalities, PLV, proteolipid vehicle

European regulators approve Janssen’s twice-yearly schizophrenia treatment

November 23, 2021 By Brian Buntz

Updated Janssen logo

Two months after receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), Janssen has won approval from the European Commission for Byannli, a six-month formulation of paliperidone palmitate. Indicated as a maintenance treatment for adults with schizophrenia, Byannli won approval based on results from the Route 6 study, which found […]

Filed Under: Drug-Device Combinations, Neurological, Pharmaceuticals Tagged With: Byannli, paliperidone palmitate

Baxter bolsters fill-finish capabilities with $100M investment in Germany

November 18, 2021 By Brian Buntz

Baxter

Baxter International (NYSE:BAX) plans to invest roughly $100 million to expand a sterile fill-finish manufacturing plant in Halle/Westfalen, Germany. BioPharma Solutions (BPS), a subsidiary of Deerfield, Illinois–based Baxter, will manage the new facility. BPS supports pharmaceutical companies through a range of offerings, including scientific support, sterile contract manufacturing and parenteral delivery systems. Get the full […]

Filed Under: Contract Services Tagged With: Baxter, Baxter International, BioPharma Solutions, BPS

AbbVie, University of Chicago lengthen oncology research partnership until 2025

November 10, 2021 By Brian Buntz

AbbVie/University of Chicago

AbbVie (NYSE: ABBV) has extended an agreement with the University of Chicago related to collaborative preclinical oncology research. The North Chicago, Illinois–based company and the university are working together on research involving biomarkers and therapeutic applications related to existing AbbVie programs. In the past, the organizations have also explored new drug delivery methods to improve […]

Filed Under: Oncology Tagged With: 3D screening, AbbVie, oncology, tumors, University of Chicago

Merck and Vesselon preclinical study reports dramatic tumor pharmacokinetics findings

September 22, 2021 By Brian Buntz

Merck/Vesselon

Merck & Co. (NSDQ:MRNA) scientists have explored fighting cancer by way of the STING (stimulator of interferon genes)-controlled innate immune pathway. Now, the company has published research in Advanced Therapeutics detailing a preclinical study with its partner Vesselon Inc. that reported impressive pharmacokinetics results related to MSA-1, a STING agonist. The researchers found that low […]

Filed Under: Featured, Oncology, Pharmaceuticals, Technology Tagged With: Keytruda, Merck, MSA-1, oncology, tumor, ultrasound, Vesselon

Rani Therapeutics’ stock jumps 69% after IPO

August 13, 2021 By Brian Buntz

Rani Therapeutics

Rani Therapeutics Holdings (NSDQ:RANI) recently announced the closing of its initial public offering (IPO) of 7,666,667 shares of its Class A common stock. The stock began trading at $11, trailing the company’s expected range of $14 to $16. Today, the stock closed at $18.61, representing a 69.18% increase. RANI shares were trading even higher on […]

Filed Under: Drug-Device Combinations Tagged With: IPO, Rani Therapeutics, Rani Therapeutics Holdings, RaniPill

Philip Morris and Carlyle continue bidding war over Vectura

August 9, 2021 By Brian Buntz

Philip Morris/Vectura/Carlyle Group

The drama surrounding the inhalable drug delivery specialist Vectura (LON:VEC) continues. On Monday, Philip Morris boosted its offer to acquire Vectura to 165 pence ($2.30) per share, beating Carlyle’s latest offer of 155 pence ($2.16). In July, Philip Morris (NYSE:PM) agreed to acquire inhaled drug delivery technology developer Vectura for $1.2 billion, drawing criticism from the American […]

Filed Under: Drug-Device Combinations

Rani Therapeutics prices $73M IPO for robotic drug-delivery pill tech

August 3, 2021 By Brian Buntz

Rani Therapeutics

Rani Therapeutics Holdings ​​(NSDQ:RANI), developer of a robotic drug-delivery pill system, generated $73.3 million in its underwritten initial public offering (IPO) of Class A common stock. The San Jose, Calif.–based company’s IPO of 6.7 million shares priced at $11 a share, generating gross proceeds of $73.3 million. The company initially targeted an IPO worth approximately […]

Filed Under: Drug-Device Combinations Tagged With: Drug delivery, Rani Therapeutics Holdings

  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS